BridgeBio Pharma, Inc.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. The company's strategy is to discover, develop, and commercialize precisely targeted medicines for patients with monogenic diseases and cancers for which there are currently no approved therapies. BridgeBio builds a portfolio of potentially life-changing therapies by leveraging its platform technologies and deep scientific expertise. The company's approach involves identifying the underlying genetic cause of a disease and then designing a tailored therapeutic intervention. BridgeBio's pipeline spans various therapeutic areas, including cardiovascular, oncology, and neurology, aiming to address significant unmet medical needs.